8-K: Reviva Pharmaceuticals Appoints Baker Tilly as New Auditor Following Moss Adams Merger, Citing Going Concern Uncertainty

Reviva Pharmaceuticals Holdings, Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, effective June 3, 2025, following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly, while also noting that prior audit reports included an explanatory paragraph regarding going concern uncertainty.

Summary

• Reviva Pharmaceuticals Holdings, Inc. (the "Company") has appointed Baker Tilly US, LLP as its new independent registered public accounting firm.
• The change was effective June 3, 2025, and resulted from the merger of the Company's previous auditor, Moss Adams LLP, with Baker Tilly US, LLP.
• Moss Adams LLP resigned as the Company's auditors on June 3, 2025, concurrently with Baker Tilly's appointment.
• Audit reports issued by Moss Adams for the fiscal years ended December 31, 2024, and 2023, did not contain adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
• However, Moss Adams' audit reports for both 2024 and 2023 included an explanatory paragraph concerning a going concern uncertainty.
• There were no disagreements on accounting principles, financial statement disclosure, or auditing scope/procedure with Moss Adams during the specified periods.
• The Company did not consult with Baker Tilly regarding accounting principles or audit opinions prior to their engagement.
• Moss Adams LLP confirmed its agreement with the statements made in the Form 8-K in a letter to the SEC dated June 6, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the explicit re-mention of the 'going concern uncertainty' in the audit reports for 2023 and 2024, which overshadows the otherwise smooth and procedural change in the auditing firm.

Positives

• The transition of the independent registered public accounting firm occurred smoothly due to a merger, rather than a dispute or performance issue.
• There were no disagreements with the former auditor, Moss Adams LLP, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.
• No reportable events requiring disclosure pursuant to Item 304(a)(1)(v) of Regulation S-K occurred during the specified periods.

Negatives

• Moss Adams' audit reports for the fiscal years ended December 31, 2024, and 2023, contained an explanatory paragraph regarding a going concern uncertainty, indicating substantial doubt about the Company's ability to continue as a going concern.

Risks

• The Company faces a significant risk related to its ability to continue as a going concern, as highlighted by the explanatory paragraph in its audit reports for 2023 and 2024.

Future Outlook

This document does not provide specific forward-looking statements or guidance regarding the Company's future financial performance or strategic direction, beyond the procedural change in its auditing firm.

Management Comments

• Narayan Prabhu, Chief Financial Officer, signed the report on behalf of Reviva Pharmaceuticals Holdings, Inc.

Industry Context

Changes in a company's independent auditor are common, especially when accounting firms merge, as seen with Moss Adams and Baker Tilly. While a smooth transition without disagreements is standard practice, the persistent mention of a 'going concern uncertainty' in audit reports is a critical disclosure that warrants close attention from investors, as it signals potential financial viability challenges that are not uncommon for early-stage biotechnology or pharmaceutical companies that are pre-revenue or heavily reliant on R&D funding.

Stakeholder Impact

• Shareholders: The disclosure of a going concern uncertainty may raise concerns about the Company's long-term financial stability and could impact investor confidence.
• Creditors: The going concern uncertainty could influence the Company's ability to secure future financing or affect terms with existing creditors.

Next Steps

• Baker Tilly US, LLP will serve as the Company's independent registered public accounting firm for future financial audits.

Key Dates

Keywords

SEC filing, 8-K, auditor change, independent registered public accounting firm, Moss Adams LLP, Baker Tilly US LLP, going concern uncertainty, financial reporting, corporate governance, Reviva Pharmaceuticals Holdings Inc., RVPH, Nasdaq Capital Market